Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer

Randomized, open label, phase II multicenter study to assess the efficacy niraparib versus niraparib +bevacizumab maintenance in patients with newly diagnosed stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery and treatment by adjuvant platinum-basedchemotherapy +/-bevacizumab.

Trial Details

NCT ID

NCT05183984

Phase

PHASE2

Sponsor

ARCAGY/ GINECO GROUP

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

Chemotherapy
Bevacizumab-Awwb
Niraparib

Locations (sample)

Angers, France|47.47156,-0.55202
Avignon, France|43.94834,4.80892
Besançon, France|47.24878,6.01815
Bordeaux, France|44.84124,-0.58046
Brest, France|48.39029,-4.48628

Key Eligibility Criteria

For inclusion in the study, patient should fulfill the following criteria:
Female patient ≥ 18 years of age.
Signed informed consent and ability to comply with treatment and follow-up.
Patient with newly diagnosed, a. Ovarian cancer, primary peritoneal cancer and/or fallopian-tube cancer, b. Histologically confirmed (based on loca…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →